- 24 apr.- 11:30

New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting

Business Wire.

Reductions in annualized relapse rates shown in pivotal trials with ozanimod were consistent in subgroups including baseline disability, gadolinium-enhanced lesion status and prior exposure to disease-modifying therapies versus interferon beta-1a (Avonex®)

Ozanimod showed effects on cortical grey matter volume and thalamic volume

- 24 apr.- 05:00

First-Quarter Figures: Sartorius Starts off Fiscal 2018 Successfully

Business Wire.
  • Group sales revenue up 11.4%; earnings1 rise 4.7%
  • Lab Products & Services continues to grow dynamically
  • Positive development of the Bioprocess Solutions Division
  • Exchange rate effects dampen profit growth
  • Forecast for the full year confirmed

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni

Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA



Banca Ifis:Osservatorio,in 2017 prezzo transazioni Npl a 18%

Stima intorno a 13mld per un totale 72mld di sofferenze cedute

Vai alla rubrica: Pianeta Camere

Real Estate

Criptovalute news